J&J Could Pay Out Up To $700M In Deal To Boost Cancer Biz
Johnson & Johnson will pay $125 million, and potentially $575 million more if certain goals are met, to help develop a drug treating blood cancers through a collaboration announced Monday with...To view the full article, register now.
Already a subscriber? Click here to view full article